Results 231 to 240 of about 1,685,264 (305)

Interleukin‐12: Central Roles in Immune Regulation and Disease Therapy

Immunology &Cell Biology, EarlyView.
IL‐12 levels are tightly regulated to balance effective protective immunity against infections and cancer with the risk of excessive inflammation and autoimmune disease. Both insufficient and excessive IL‐12 activity can therefore be detrimental, highlighting the importance of precisely controlling its production and signaling. ABSTRACT Interleukin‐12 (
Anthi Psoma, Geert van den Bogaart
wiley   +1 more source

Preventing infections after CD19‐directed chimeric antigen receptor T‐cell therapies for lymphoma: a consensus practice statement

Internal Medicine Journal, EarlyView.
Abstract Chimeric antigen receptor (CAR) T‐cell therapies directed against cluster of differentiation 19 (CD19) are a standard of care for relapsed or refractory B‐cell lymphomas. Infection is the leading cause of non‐relapse mortality, and this risk may persist for years after CAR T‐cell receipt.
Aine Hurley, Philip George, Gemma Reynolds, Adam Stewart, Hang Quach, Nicole O'Leary, Zoe McQuilten, Andrea S. Henden, Lynette Chee, Chan Y. Cheah, Olivia Bupha‐Intr, Emily Blyth, Ben Teh, Monica Slavin, Michael Dickinson, Robert Weinkove   +15 more
wiley   +1 more source

Evaluation of seroprevalence and risk factors for Q fever (<i>Coxiella burnetii</i>) infection in sheep from Tiaret province, northwestern Algeria. [PDF]

Open Vet J
Safer I, Mahouz F, Ayad MA, Hemida H, Aissat S, Abdelli A, Nadăş GC, Derrar S.   +7 more
europepmc   +1 more source

Targeting the miR‐224‐5p/PTEN pathway: A previously under‐characterized strategy to attenuate mesangial cell injury and predict prognosis in diabetic nephropathy

Journal of Diabetes Investigation, EarlyView.
Serum miR‐224‐5p levels are progressively elevated in diabetic nephropathy (DN) and serve as an independent predictor of a decline in eGFR of ≥30% over 2 years. Mechanistically, miR‐224‐5p directly targets PTEN 3’‐UTR, suppressing PTEN and the activation of the AKT pathway in high‐glucose‐stimulated mesangial cells.
Yanxia Gao, Xiaohui Zhang, Peng Lu, Qiang Wang   +3 more
wiley   +1 more source

Control of human Q fever by vaccination: the journey to Q-VAX and beyond. [PDF]

Infect Immun
Heinzen RA, Pierce KN, Voth DE, Stenos J, Graves S, Long CM.   +5 more
europepmc   +1 more source

Association of atherogenic index of plasma with gestational diabetes mellitus and birth weight outcomes, and the mediating role of blood glucose

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims This study aimed to examine the associations of maternal first‐trimester atherogenic index of plasma (AIP) with gestational diabetes mellitus (GDM) and birth weight outcomes, and the mediating role of second‐trimester blood glucose. Methods This prospective cohort study included 5,706 pregnant women without pre‐existing diabetes or other ...
Doudou Zhao, Yanfang Song, Nan Li, Yu Zhang, Yiting Li, Kangxin Wang, Yang Mi, Lei Shang, Pengfei Qu   +8 more
wiley   +1 more source

Human Q fever outbreak investigation and management in six European countries: a One Health compendium of practices and recommendations.

CMI Commun
Hurtado A, Rousset E, Couesnon A, de Haan T, Dijkstra F, Fischer SF, Fournier PE, García-Pérez AL, Jado I, Jourdain E, Mertens-Scholz K, McNeilly TN, Neale S, Osborne JC, Van Esbroeck M, Mori M, van den Brom R.   +16 more
europepmc   +1 more source

Clinical characteristics of sporadic acute Q fever diagnosed by metagenomic next-generation sequencing: a retrospective analysis and literature review in China. [PDF]

BMC Infect Dis
Chen J, Li X, Deng Z, Ying Y, Lu M.
europepmc   +1 more source

Giant cellulitis‐like Sweet's syndrome induced by gilteritinib

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Juan de Luque‐Fernández, Irene Rivera‐Ruiz, Irene Suárez‐Vergne, Inmaculada Sánchez‐Ramírez, Manuel Galán‐Gutiérrez, Antonio José Vélez García‐Nieto   +5 more
wiley   +1 more source

A randomized phase 2 trial of socrodeucitinib in moderate‐to‐severe plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In moderate‐to‐severe plaque psoriasis, socrodeucitinib (6 mg/12 mg) significantly outperformed placebo at week 12: PASI 75 response rates 28.6%/72.1% vs. 7.5%. Meanwhile, socrodeucitinib illustrated a favourable safety and tolerability profile, warranting further study.
Ling Han, Songmei Geng, Yangfeng Ding, Shifa Zhang, Xiaohua Wang, Fengming Hu, Jianguo Li, Chao Ci, Yayu Hu, Rixin Chen, Jianping Zhang, Xiaoyong Zhou, Aijun Chen, Chunlei Zhang, Tiechi Lei, Yanyan Feng, Yu Wang, Zudong Meng, Yan Zhou, Mingkai Ji, Wei Liu, Yunting Wu, Qianying Chen, Siyi Wang, Jinhua Xu   +24 more
wiley   +1 more source